IRulya Therapeutics Inc.(IRLA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 2 days
PROFIT SINCE LAST BUY
+0.05% ▲
LAST CLOSE
$39.8
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IRLA

11/13/2026: IRLA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

IRulya Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing disease-modifying inhaled therapies for severe respiratory conditions. The company's primary value proposition centers on its lead asset, LAM-001, which targets dysfunctional mTOR signaling directly in the lungs to treat rare pulmonary diseases. Key strengths include a strengthened cash runway extending into late 2028 and a specialized focus on high-unmet-need orphan indications. However, the company faces high execution risks, pre-commercial financial losses, and complete reliance on upcoming Phase 2 clinical data readouts. The stock suits growth-oriented or momentum investors comfortable with clinical binary risk, requiring close monitoring of pipeline trial progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveHigh potential upside exists if clinical trials for LAM-001 successfully validate its disease-modifying capabilities in rare pulmonary indications.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp directional moves around clinical trial readouts, corporate updates, and milestone announcements.
Value investorWeak fitThe company lacks commercial revenue and positive earnings, rendering traditional valuation metrics inapplicable.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for clinical drug development.
Low-risk investorWeak fitClinical-stage biotechnology investing entails high binary clinical trial risk and substantial price volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology equities frequently experience sharp swings based on market sentiment and upcoming pipeline catalysts.
Valuation riskHighValuations rely heavily on prospective clinical success assumptions rather than present earnings or cash flow generation.
Competition risk (rare pulmonary therapeutics competition)Medium / highThe company competes with well-capitalized biotechnology and pharmaceutical firms targeting overlapping respiratory indications.
Business qualityMediumThe firm features a focused scientific strategy and experienced leadership, though it remains pre-revenue.
Dividend incomeLow / noneNo dividend distributions are paid to equity holders.
Execution riskHighFuture enterprise value depends entirely on successful clinical trial execution, regulatory navigation, and eventual commercialization.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 431.49M USD
Price to earnings Ratio -
1Y Target Price 75
Price to earnings Ratio -
1Y Target Price 75
Volume (30-day avg) 87.4K shares
Beta 1.79
52 Weeks Range 15.10 - 910.00
Updated Date 11/15/2026
52 Weeks Range 15.10 - 910.00
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -214.01

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 87.22%
Avg. Invested days 26
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IRLA receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft company fundamentals, and weak price momentum.

Company Fundamentals

★★★★★
IRLA has soft overall fundamentals (2 stars), with moderate financial health, soft growth momentum, and soft ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-47.8%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
IRLA's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
IRLA's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-47.8%, negative) and free-cash-flow growth (-29.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 12.1% (soft) and 6.3% of outstanding shares are publicly tradable (soft). Insider ownership of 1.01% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Ikarian Capital, LLC 0.36%
Millennium Management LLC 0.35%
Balyasny Asset Management LLC 0.34%
Squadron Capital Management LLC 0.20%
Shay Capital LLC 0.09%

Unit Economics (Per $1K Revenue)

★★★★★
IRLA generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -3.98% (Tax Credit)

Quantitative Style Profile

★★★★★
IRLA has a Value-Oriented profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Drug DevelopmentFuture commercialization or licensing of clinical assets like LAM-001 for rare respiratory conditions.The company currently generates zero commercial revenue and operates entirely as a clinical-stage research entity.

Earnings Date

Report Date 2026-11-11
When -
Estimate -0.83
Actual 50

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -31.51%
Return on Equity (TTM) -153.84%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 315.51M
Price to Sales(TTM) -
Enterprise Value 315.51M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 1.44
Shares Outstanding 10.84M
Shares Floating 679.68K
Shares Outstanding 10.84M
Shares Floating 679.68K
Percent Insiders 1.01
Percent Institutions 12.11

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.